基于iTRAQ技术的非小细胞肺癌和肺结核“同病异证”和“异病同证”的研究

Non-small cell lung cancer (NSCLC) and tuberculosis are still serious health problems, and traditional Chinese medicine (TCM) plays an irreplaceable role in the treatment. But the subjectivity and uncertainty of TCM syndrome differentiation limits its effect. Therefore, it’s essential to the reveal the nature of TCM syndrome. Research we can find mostly use some classical methods such as two-dimensional electrophoresis, MALDI-TOF-MS and SELDI-TOF-MS rather than more advanced technologies such as iTRAQ. We didn’t find any research on "different diseases with the same syndrome" about NSCLC and tuberculosis, either. In this research, we will look for differentially expressed proteins between two different TCM syndromes of NSCLC (the splenic asthenia and phlegm-damp syndrome and Qi-Yin deficiency syndrome), and the same TCM syndrome (Qi-Yin deficiency syndrome) of NSCLC and tuberculosis by iTRAQ combined with HPLC-MS/MS. The object is to find out the biological material foundation and biological markers of different TCM syndromes so as to reveal their nature, and to provide the basis for accurate TCM diagnosis and treatment.

非小细胞肺癌和肺结核目前仍是严重危害人类健康的疾病，中医药在其诊疗中发挥着不可替代的作用，但中医辨证的主观性和不确定性制约着诊疗特色的发挥。因此，对中医证候进行客观化的研究以揭示其本质是非常必要的。已有的关于非小细胞肺癌和肺结核中医证候的研究应用的皆为双向电泳、MALDI-TOF-MS和 SELDI-TOF-MS等比较传统的技术，少有iTRAQ等较为先进的蛋白质组学技术，亦未见关于非小细胞肺癌和肺结核“异病同证”的研究。因此，本项目拟采用iTRAQ联合液相串联质谱技术，对非小细胞肺癌的两个不同证型（“同病异证”）脾虚痰湿证和气阴两虚证，及非小细胞肺癌和肺结核的同一证型（“异病同证”）气阴两虚证进行研究，寻找差异蛋白质，试图发现不同证候的生物学物质基础及生物标志物，以揭示证候的本质，阐释其科学内涵及发生发展及演化机制，为证候客观化和精确化应用研究及中医的精确诊断和治疗提供依据。